BMY — BRISTOL MYERS SQUIBB CO
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 14272 ·
Last close
$62.40
Market Cap
$127.47B
52W High
$68.64
52W Low
$41.13
ADV30
10,512,173
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 11,489,000,000 | 8,068,000,000 | 3,365,000,000 | 2,677,000,000 | 86,476,000,000 | 9,574,000,000 | 66,374,000,000 |
| Dec 2025 | 12,503,000,000 | 8,406,000,000 | 2,813,000,000 | 1,087,000,000 | 90,038,000,000 | 10,209,000,000 | 71,532,000,000 |
| Sep 2025 | 12,222,000,000 | 8,787,000,000 | 3,639,000,000 | 2,201,000,000 | 96,889,000,000 | 15,726,000,000 | 78,289,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$12,782,000,000
Investing CF
$-4,905,000,000
Financing CF
$-11,709,000,000
CapEx
$-1,342,000,000
Dividends Paid
$-5,095,000,000
Buybacks
$0
EPS Diluted TTM
$4.54
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$20,316,000,000
Inventory
$2,737,000,000
Receivables
$12,999,000,000
ST Investments
$2,345,000,000
EBIT TTM
$13,640,000,000
Pretax Income TTM
$11,910,000,000
Interest Exp TTM
$1,730,000,000
Analysts
23
Yahoo Snapshot (yfinance, live)
Total Revenue
$49,186,000,896
EBITDA
$18,929,999,872
Free Cash Flow
$8,114,375,168
Enterprise Value
$163,984,359,424
Total Cash
$11,066,999,808
Total Debt
$45,053,001,728
Shares Out
2,042,714,656
Trailing EPS
$4.54
Book Value
$10.93
ROE
46.6%
ROA
10.7%
Div Yield
3.96%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 48,195,000,000 | 13,724,000,000 | 7,054,000,000 | 90,038,000,000 | 71,532,000,000 | 18,473,000,000 | 14,156,000,000 |
| Dec 2024 | 48,300,000,000 | 5,887,000,000 | -8,948,000,000 | 92,603,000,000 | 76,215,000,000 | 16,335,000,000 | 15,190,000,000 |
| Dec 2023 | 45,006,000,000 | 8,195,000,000 | 8,025,000,000 | 95,159,000,000 | 65,674,000,000 | 29,430,000,000 | 13,860,000,000 |
| Dec 2022 | 46,159,000,000 | 9,104,000,000 | 6,327,000,000 | 96,820,000,000 | 65,702,000,000 | 31,061,000,000 | 13,066,000,000 |
TTM Snapshot
Revenues TTM
$45,277,000,000
NetIncome TTM
$7,201,000,000
OpCashFlow TTM
$0
Assets (Latest)
$90,038,000,000
Forward EPS
$6.56
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $62.50 · spot: $62.40 · call volume: 1,780 · put volume: 1,763
Expected Move to 2026-12-18:
±$7.78
(12.47%) —
implied range
$54.62 –
$70.18
· ATM straddle on $62.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NONOF | NOVO NORDISK A S | $127.58B | $38.15 | — |
| NVO | NOVO NORDISK A S | $126.77B | $37.91 | — |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.51B | $522.81 | — |
| PFE | PFIZER INC | $162.55B | $28.52 | — |
| SNY | Sanofi | $98.79B | $41.23 | — |
News headlines (Yahoo Finance, 1h cache)
Bristol Myers trial revisions shake confidence in new class of fibrosis drugs
2026-09-30 16:22 · Yahoo
Bristol Myers Squibb’s Dividend Sustainability Hinges on One Critical Cash Flow Metric
2026-09-30 15:45 · Yahoo
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
2026-09-30 12:00 · Yahoo
CAR T-Cell Therapy Market Forecasts Growth from $7.24B (2026) to $13.78B by 2031, Profiling Bristol-Myers Squibb, Gilead Sciences, Novartis & J&J
2026-09-30 08:47 · Yahoo
How Strong Phase 3 MRD Data for ZENBEXUS in Myeloma Could Impact Bristol Myers Squibb (BMY) Investors
2026-09-30 01:08 · Yahoo
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
2026-09-29 22:42 · Yahoo
Bristol Myers Squibb (BMY) Reported 41.1% MRD Negative Responses In Phase 3 Trial
2026-09-29 19:06 · Yahoo
Bristol Myers Squibb (BMY) Stock Trades Below Fair Value As Caution Lingers
2026-09-29 10:06 · Yahoo
3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation
2026-09-29 09:41 · Yahoo
PFE vs. BMY: Each Faces a $22 Billion+ Patent Cliff. One Dividend Looks Much Safer
2026-09-30 15:34 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.